FDC346.40

FDC Limited

· Pharma & Health
₹ CrorePeersIOLCPMOREPENLABINNOVACAPORCHPHARMASENORESGUJTHEMRPGLIFESANOFIMcap ₹5,640 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)242.82235.51224.97224.97
Receivable Days (DSO)22.0518.8525.5125.51
Payable Days (DPO)116.16128.83130.95139.11
Cash Conversion Cycle (days)148.71125.53119.53111.37
Working Capital Turnover2.422.912.832.85
Asset Turnover0.790.780.740.74
Cash Conversion (CFO/Net Income)0.721.190.710.71
CFO/EBITDA0.650.980.580.58
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.